| Similar Articles |
|---|
 |
The Motley Fool
March 16, 2011
Brian Orelli |
Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial.   |
The Motley Fool
November 17, 2011
Brian Orelli |
In Biotech, Approval's Important, but It's the Launch That Counts With an approval in hand, Incyte's investors are still nervous. |
American Family Physician
May 1, 2004 |
Polycythemia Vera A general overview on Polycythemia Vera, a disease in which the body makes too many red blood cells. |
BusinessWeek
December 6, 2004
Catherine Arnst |
Cord Blood To The Rescue A study in the Nov. 25 issue of The New England Journal of Medicine confirms that stem cells in blood extracted from the umbilical cords of newborns can help leukemia patients |
The Motley Fool
November 25, 2009
Brian Orelli |
Novartis Didn't Know JAK, Until Now Incyte has something to be thankful for this week. Novartis is giving the company a wad of cash to license its most promising drug candidate for myelofibrosis |
The Motley Fool
December 11, 2008
Brian Orelli |
ASH Wrap-Up: Alphabet Soup and Drugs Let's take a look at the data that came out of the American Society of Hematology meeting regarding pharmaceutical companies' medications for blood diseases. |
The Motley Fool
September 27, 2007
Brian Orelli |
Incyte's Double Dose of Trial News With two drugs providing good results in preliminary trials, and another five medications in early-stage clinicals, Incyte is a shining example of a developmental-stage drugmaker. Investors, take note. |
The Motley Fool
January 7, 2009
Brian Orelli |
A One-Hit Wonder Goes for No. 2 Onyx Pharmaceuticals announces its second license in the last few months. |
American Family Physician
November 1, 2000
Neil Abramson & Becky Melton |
Leukocytosis: Basics of Clinical Assessment Leukocytosis, a common laboratory finding, is most often due to relatively benign conditions (infections or inflammatory processes). Much less common but more serious causes include primary bone marrow disorders... |
The Motley Fool
October 14, 2011
Sean Williams |
7 FDA Decisions You Can't Afford to Ignore in Q4 These stocks are bound to move as the FDA weighs in on their prospective drugs in Q4: Bristol-Myers... BioSante... Teva... Regeneron... Transcept... Incyte... Antares Pharma... |
American Family Physician
May 15, 2002
Doron Schneider |
Diagnosis and Treatment of Paget's Disease of Bone Paget's disease of bone (also known as osteitis deformans) is a nonmalignant disease involving accelerated bone resorption followed by deposition of dense, chaotic, and ineffectively mineralized bone matrix... |
The Motley Fool
December 21, 2010
Brian Orelli |
Our Drug Is Better Than Your Drug Without a question, Incyte's compound, INCB18424, works in myelofibrosis. Now that it has positive phase 3 results, it's time to get a brand name for the thing; INCB18424 just isn't that catchy. |
The Motley Fool
May 19, 2010
Brian Orelli |
The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd. |
BusinessWeek
May 24, 2004
Arlene Weintraub |
Want To Bank Your Own Stem Cells? One Los Angeles startup believes everyone should, to be ready when regenerative therapies start hitting the market |
Popular Mechanics
December 16, 2008
Michael Milstein |
Bringing Stem Cells to War: Meet the Blood Pharmers Fresher blood is better than stale: It carries more oxygen and, when transfused into patients, speeds recovery. |
Salon.com
July 17, 2000
Alix Christie |
The cord-blood controversy First we were supposed to eat the placenta. Now we're supposed to freeze it. |
BusinessWeek
June 21, 2004
Catherine Arnst |
Guard Your Bones Osteoporosis is one of the biggest health risks facing older women. What can be done to help prevent this disease? |
HHMI Bulletin
May 2011
Dan Ferber |
Revealing the Biological Complexity of Bones Bones are the body's framework and support, our strongest tissues. Unlike the scaffold of a building, however, bones are anything but inert. They pulse with life and their maintenance requires a surprisingly delicate balancing act. |
The Motley Fool
July 1, 2011
Alex Crawford |
3 Biotech Drugs With Promising Phase III Data, Moving Into FDA Review Do these drugs have a chance of FDA approval? |
The Motley Fool
November 28, 2009
Rick Aristotle Munarriz |
A Fool Looks Back Novartis and News Corp were in the news this week for exploring and making deals. Retailers also were in the spotlight. |
IEEE Spectrum
October 2007
Morgen E. Peck |
Imperceptible Vibrations Slow Weight Gain New research by engineers and scientists show how low-level mechanical signals inhibit fat-cell production in mice. |
Chemistry World
October 15, 2007
Jonathan Edwards |
Bones Heal Faster with Nanocrystals A nanocrystalline cement could help bone grafts to heal more quickly, Chinese scientists have claimed. |
Science News
June 3, 2006 |
Timeline: From the May 30, 1936, Issue 124 Earth Tremors in 10 Days at Mt. Lassen... Warmth Necessary for Working of Body's Blood Factory... Develops Ray Receiver for Signaling with Invisible Rays... |
Seasoned Cooking
July 2005
Michael Fick |
Dem Bones Unless we patients, our doctors, and the whole medical profession change our acts, our aging population, lazier lifestyles, and junk food diets will lead to half of Americans over the age of 50 having osteoporosis or being at high risk for it. |
